Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?
Simply Wall St.
·
2026-06-12T01:15:37Z
ARQT
Arcutis Biotherapeutics, Inc.
NMS
$24.38
-0.21
(-0.85%)
Extended · +1.97σ
Grade B
News · ARQT
Full news feed →
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
MarketBeat
·
2026-06-10T00:02:51Z
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion
Simply Wall St.
·
2026-05-09T05:19:31Z
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby
·
2026-05-07T12:30:00Z
Arcutis Biotherapeutics Q1 Earnings Call Highlights
MarketBeat
·
2026-05-06T22:59:43Z
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Zacks
·
2026-05-06T21:25:03Z
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks
·
2026-04-30T14:00:08Z
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Zacks
·
2026-04-29T14:00:27Z
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves
Simply Wall St.
·
2026-04-24T00:16:05Z
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target
Simply Wall St.
·
2026-04-23T18:05:34Z